Combining two cutting-edge techniques reveals that neurons in the prefrontal cortex are built to respond to reward or aversion, a finding with implications for treating mental illness and addictions.
May 26, 2016 - By Andrew Myers
The prefrontal cortex plays a mysterious yet central role in the mammalian brain. It has been linked to mood regulation, and different cells in the prefrontal cortex seem to respond to positive and negative experiences. How the prefrontal cortex governs these opposing processes of reward or aversion, however, has been largely unknown.
In a new paper published online May 26 in Cell, researchers at Stanford, led by Karl Deisseroth, have united two transformational research techniques to show how the prefrontal circuits that process positive and negative experiences are distinctly and fundamentally different from one another, both in how they function and in how they are wired to other parts of the brain.
“These cells are built differently,” said Deisseroth, MD, PhD, professor of bioengineering and of psychiatry and behavioral sciences. “They didn’t start the same and then change their nature with recent experience. They appear wired specifically to communicate positive or negative experience.”
This has deep implications for both our understanding of how reward and aversion work, but also for the potential development of drugs or other therapies to treat drug addiction and mental illnesses tied to reward and aversion.
The full dream
Optogenetics is a technique for genetically modifying cells — neurons, in this case — in living animals so that their function can be turned on and off with light. CLARITY is a remarkable feat of chemical engineering in which the fatty, opaque tissues that constitute an intact, non-living brain are removed, leaving behind a transparent physical structure with all of its parts and wiring exactly in place.
“Unifying optogenetics and CLARITY enables us to discover how behavior arises from whole-brain circuit activity patterns without losing sight of individual neurons,” said Deisseroth, who holds the D.H. Chen Professorship. “We can obtain the fine detail and the big picture at the same time.”
Previously it has not been possible, for example, to determine whether the neurons in the prefrontal cortex that are active during distinct experiences are physically different kinds of cells or whether they simply receive different information. This distinction matters a great deal when thinking about the basic processing in this part of the brain, as well as when considering possible therapies targeted to cell type.
Prior techniques allowed researchers to either listen in on the activity of a group of neurons using electrodes or to image brain activity. But these techniques can’t report how these cells are connected across an individual subject’s brain as researchers track cell activity during behavior.
Now, by uniting optogenetics and CLARITY, Deisseroth’s team has shown how to study both the function and the wiring of neurons simultaneously, thus hitting a crucial target for the National Institutes of Health’s BRAIN Initiative.
“This is a first look at these cells in detail while retaining the link to activity during behavior,” Deisseroth said. “It’s like getting to know the various components of a computer circuit, but also digging deeper into what their individual properties are, how they are wired together and how they are used in the circuit. Ultimately, it helps you understand how it all works.”
The first facet of the research involved CLARITY. It allowed the researchers to trace specific pathways and “label” specific molecular structures within the brains of the subjects, which in this case were mice. The researchers gave the mice positive or negative stimuli. Only the neurons that had been strongly active during the experience became labeled — along with their outgoing connections — allowing effective tracing of the distinct circuits through the brain.
Using optogenetics, the researchers controlled specific neurons, within the living animals that had been active during positive or negative experiences. The team was able to then evaluate how those particular neurons affect behavioral outcomes.
This is a first look at these cells in detail while retaining the link to activity during behavior.
Those mice had been optogenetically modified so that the cells becoming light-sensitive were only those that were most active during the positive or negative experience provided. For instance, the team was able to turn on only the positive-experience-associated cells to observe behavior in the mice. In effect, they were able to fool the mice into thinking they were experiencing a positive-valence stimulus, such as chocolate or cocaine, in order to observe how behavior changed.
By pairing the techniques in the same experiment, Deisseroth’s team was able to determine not only that the molecular signature of the positive cells was different from those of the negative cells — both cocaine and chocolate associated with cells producing a particular molecular marker called NPAS4 — but also that the positive and negative cells were wired to distant places in the brain in fundamentally differing ways.
Given the strong linkage between the prefrontal cortex and various psychiatric illness, Deisseroth said this study opens the possibility in future studies to identify and target different cell types with diverse therapeutic approaches, including drugs or external stimulation techniques.
Deisseroth said the findings of this study, as with his other transformational work, are the result of a remarkable interdisciplinary effort. In this case, the team included Liqun Luo, PhD, a Stanford professor of biology whose lab developed a mouse line that was used for one of several different experience-dependent labeling strategies in the paper, and Jennifer McNab, PhD, a Stanford assistant professor of radiology who helped quantify the cellular pathways through the brain. The experimental work was led by postdoctoral researchers Li Ye and William Allen, and by Kimberly Thompson, a graduate student. All three were lead authors of the paper.
“The Stanford community is an incredible place for interdisciplinary research,” Deisseroth said. “The right people are always just a short walk away. This study and its implications are a testament to the value of that environment.”
The research is supported in part by the National Institute of Mental Health, National Institute on Drug Abuse, the Wiegers Family Fund, the Howard Hughes Medical Institute, the U.S. Army Research Laboratory and the Defense Advanced Research Projects Agency.
Stanford’s departments of Bioengineering and of Psychiatry and Behavioral Sciences also supported the work. The Department of Bioengineering is operated jointly by the School of Medicine and the School of Engineering.
About Stanford Medicine
Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.